Circulating blood group-related antigen(s) in cancer patients detected by the monoclonal antibodies produced against hepatocellular carcinoma cell line.
Circulating blood group-related antigen(s) in cancer patients detected by the monoclonal antibodies produced against hepatocellular carcinoma cell line.
复制标题
通过针对肝细胞癌细胞系产生的单克隆抗体检测癌症患者的循环血型相关抗原。
DOI：
--
复制
发表时间：
1985
期刊：
影响因子：
--
通讯作者：
A. Yachi
中科院分区：
文献类型：
--
作者：
K. Imai;T. Sasanami;T. Nakanishi;T. Noguchi;A. Yachi
两种针对人肝癌细胞系产生的小鼠单克隆抗体（mab） S1和S3可以识别H （II型）抗原和di focusyl II型结构（y抗原）。两种单克隆抗体均与手术切除的肝癌组织发生反应。采用这些单克隆抗体的双决定因素酶免疫测定（DDEI）成功地在免疫肝癌细胞系释放或脱落的上清液中检测到相应的抗原。DDEI还显示，这些抗体与癌症患者血清中相应的抗原反应。在O型血献血者的血清中，原发性肝癌患者的抗原浓度明显高于正常对照组。一些O型血的胆囊癌、肺癌和胰腺癌患者的抗原水平也明显较高。1例B型卵巢癌患者的抗原浓度高于正常O型血供者，提示血清中相应抗原的碳水化合物结构发生了变化。这些数据表明，由于恶性转化，细胞中抗原的释放或脱落可能会增加，从而导致某些癌症患者血清中抗原的含量较高。
Two murine monoclonal antibodies (MAbs) S1 and S3 produced against a human hepatoma cell line were found to recognize both H (type II) antigen and difucosyl type II structure (Y-antigen). Both MAbs reacted with hepatoma tissues obtained from surgical resection. A double determinant enzyme immunoassay (DDEI) employing these MAbs successfully detected the corresponding antigen(s) in the supernatant which is either released or shed from the immunizing hepatoma cell line. DDEI also revealed that these antibodies reacted with the corresponding antigen(s) in the sera from cancer patients. Among the sera from O blood group donors, individuals with primary hepatoma showed markedly higher levels of antigen concentration than the normal control group. Several cases with gall bladder, lung and pancreas carcinomas, which are of O blood type, also had significantly higher levels of antigen. One case with ovarian cancer of B blood type showed higher antigen concentration than normal O blood group donors suggesting a change in the carbohydrate structure of the corresponding antigen(s) in the serum. These data suggest that the release or the shedding of the antigen(s) from the cells may increase due to the malignant transformation, resulting in higher amounts of the antigen(s) in the serum of certain cancer patients.